Search Results - "Mohs, R"

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients by MOHS, R. C, DOODY, R. S, MORRIS, J. C, IENI, J. R, ROGERS, S. L, PERDOMO, C. A, PRATT, R. D

“…To examine the effects of donepezil compared with placebo on the preservation of function in patients with AD over a 1-year period. This was a prospective,…”
Get full text

The future is now: Model-based clinical trial design for Alzheimer's disease by Romero, K, Ito, K, Rogers, JA, Polhamus, D, Qiu, R, Stephenson, D, Mohs, R, Lalonde, R, Sinha, V, Wang, Y, Brown, D, Isaac, M, Vamvakas, S, Hemmings, R, Pani, L, Bain, LJ, Corrigan, B

“…Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design…”
Get full text

Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology by Doody, R S, Stevens, J C, Beck, C, Dubinsky, R M, Kaye, J A, Gwyther, L, Mohs, R C, Thal, L J, Whitehouse, P J, DeKosky, S T, Cummings, J L

“…To define and investigate key issues in the management of dementia and to make literature-based treatment recommendations. The authors searched the literature…”
Get full text

AMPA potentiator treatment of cognitive deficits in Alzheimer disease by CHAPPELL, A. S, GONZALES, C, WILLIAMS, J, WITTE, M. M, MOHS, R. C, SPERLING, R

“…To investigate the efficacy and safety of the positive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid modulator LY451395 in patients with mild to…”
Get full text

Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease by Davis, Kenneth L, Mohs, Richard C, Marin, Deborah, Purohit, Dushyant P, Perl, Daniel P, Lantz, Melinda, Austin, Gregory, Haroutunian, Vahram

“…CONTEXT A central tenet of Alzheimer disease (AD) is the loss of cortical cholinergic function and cholinergic markers in postmortem brain specimens. Whether…”
Get full text

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease by ROGERS, S. L, FARLOW, M. R, DOODY, R. S, MOHS, R, FRIEDHOFF, L. T

Get full text

Symptoms, Cognitive Functioning, and Adaptive Skills in Geriatric Patients With Lifelong Schizophrenia: A Comparison Across Treatment Sites by Harvey, Philip D., Howanitz, Evelyn, Parrella, Michael, White, Leonard, Davidson, Michael, Mohs, Richard C., Hoblyn, Jennifer, Davis, Kenneth L.

“…OBJECTIVE: Although many geriatric patients with schizophrenia have been referred to nursing home care, little is known about their characteristics. Across…”
Get full text

Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype by Gibson, G. E., Haroutunian, V., Zhang, H., Park, L. C. H., Shi, Q., Lesser, M., Mohs, R. C., Sheu, R. K-F., Blass, J. P.

“…Brain metabolism and the activity of the α‐ketoglutarate dehydrogenase complex (KGDHC), a mitochondrial enzyme, are diminished in brains from patients with…”
Get full text

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery by Welsh, K A, Butters, N, Mohs, R C, Beekly, D, Edland, S, Fillenbaum, G, Heyman, A

“…The neuropsychological tests developed for the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) are currently used to measure cognitive…”
Get full text

Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3 by Liu-Seifert, Hong, Siemers, E., Sundell, K., Mynderse, M., Cummings, J., Mohs, R., Aisen, P.

“…Background Clinical progression of Alzheimer’s disease is characterized by impairment in cognition and function. Objective To assess the relationship between…”
Get full text

Cerebral infarcts in patients with autopsy-proven Alzheimer's disease: CERAD, part XVIII by HEYMAN, A, FILLENBAUM, G. G, WELSH-BOHMER, K. A, GEARING, M, MIRRA, S. S, MOHS, R. C, PETERSON, B. L, PIEPER, C. F

Get full text

The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials by Mohs, R. C.

“…This paper describes the natural history of the clinical syndrome of Alzheimer's disease (AD) including the cognitive deficit, the neuropsychiatric symptoms,…”
Get full text

Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients by Harvey, Philip D, Silverman, Jeremy M, Mohs, Richard C, Parrella, Michael, White, Leonard, Powchik, Peter, Davidson, Michael, Davis, Kenneth L

“…Background: Geriatric schizophrenic patients with a chronic course of institutionalization manifest cognitive and functional impairments that implicate decline…”
Get full text

Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease by Mohs, Richard C., Schmeidler, James, Aryan, Mosen

“…This paper reviews data on the natural history of symptoms in patients with Alzheimer's disease (AD) and describes some of the problems encountered in…”
Get full text

Neurocognitive Assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project Schizophrenia Trial: Development, Methodology, and Rationale by Keefe, Richard S. E, Mohs, Richard C, Bilder, Robert M, Harvey, Philip D, Green, Michael F, Meltzer, Herbert Y, Gold, James M, Sano, Mary

“…Patients with schizophrenia are severely impaired in crucial aspects of neurocognitive function. This impairment is the strongest clinical correlate of poor…”
Get full text

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration by Stern, R G, Mohs, R C, Davidson, M, Schmeidler, J, Silverman, J, Kramer-Ginsberg, E, Searcey, T, Bierer, L, Davis, K L

“…This study measured the annual rate of cognitive change in patients with Alzheimer's disease and determined the effects of clinical variables on that rate. It…”
Get more information

The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease by Morris, J C, Edland, S, Clark, C, Galasko, D, Koss, E, Mohs, R, van Belle, G, Fillenbaum, G, Heyman, A

“…Reliable information on rate of progression of cognitive impairment in probable Alzheimer's disease (AD) is important for evaluating possible beneficial…”
Get full text

Type 2 Diabetes Is Negatively Associated With Alzheimer's Disease Neuropathology by Beeri, Michal Schnaider, Silverman, Jeremy M., Davis, Kenneth L., Marin, Deborah, Grossman, Hillel Z., Schmeidler, James, Purohit, Dushyant P., Perl, Daniel P., Davidson, Michael, Mohs, Richard C., Haroutunian, Vahram

“…Background. In cross-sectional and longitudinal studies, type 2 diabetes has been positively associated with the risk of Alzheimer's disease (AD). The present…”
Get full text

Genome Scan of Schizophrenia by Levinson, Douglas F., Mahtani, Melanie M., Nancarrow, Derek J., Brown, Donna M., Kruglyak, Leonid, Kirby, Andrew, Hayward, Nicholas K., Crowe, Raymond R., Andreasen, Nancy C., Black, Donald W., Silverman, Jeremy M., Endicott, Jean, Sharpe, Lawrence, Mohs, Richard C., Siever, Larry J., Walters, Marilyn K., Lennon, David P., Jones, Helen L., Nertney, Deborah A., Daly, Mark J., Gladis, Madeline, Mowry, Bryan J.

“…OBJECTIVE: The goal of this study was to identify chromosomal regions likely to contain schizophrenia susceptibility genes. METHOD: A genomewide map of 310…”
Get full text

Age-related shift in brain region activity during successful memory performance by Hazlett, E.A, Buchsbaum, M.S, Mohs, R.C, Spiegel–Cohen, J, Wei, T.-C, Azueta, R, Haznedar, M.M, Singer, M.B, Shihabuddin, L, Luu–Hsia, C, Harvey, P.D

“…Coregistered positron emission tomography (PET)/magnetic resonance imaging (MRI) was used to characterize brain function in 70 volunteers, aged 20–87 years,…”
Get full text